VAY 736

Drug Profile

VAY 736

Alternative Names: NOV-5; VAY-736

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys; Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MorphoSys; Novartis
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Neuropsychotherapeutics; Skin disorder therapies
  • Mechanism of Action B-cell activation factor receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 07 Feb 2018 Novartis completes phase II trial in Sjogren's syndrome in Germany (NCT02149420)
  • 22 Jan 2018 Novartis completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Germany (IV) (SC) (NCT02675803)
  • 17 Jan 2018 Novartis Pharmaceuticals plans a phase Ib trial in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) (CVAY736Y2102; NCT03400176)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top